Literature DB >> 19049702

Glomerular crescent formation in renal amyloidosis. A clinicopathological study and demonstration of upregulated cell-mediated immunity.

K Masutani1, M Nagata, H Ikeda, K Takeda, R Katafuchi, H Hirakata, K Tsuruya, M Iida.   

Abstract

BACKGROUND: Several studies examined glomerular crescents associated with renal amyloidosis. However, the incidence of crescents, the association between the 2 lesions, treatment and outcome are still controversial. PATIENTS AND METHODS: We studied 107 consecutive biopsies of renal amyloidosis, and found cellular or fibrocellular crescents in 13 cases (12.1%). We investigated the clinical characteristics, pathological findings, treatment and outcome. We also performed immunohistochemical staining using T cell, macrophage and osteopontin (OPN) markers.
RESULTS: Amyloid was of the AA type in 12 cases, and all patients had rheumatoid arthritis. Six cases with AA amyloidosis had crescentic glomerulonephritis (CrGN), and 5 presented with rapidly progressive glomerulonephritis (RPGN). The percentage of crescents correlated negatively with serum albumin (r = -0.83, p < 0.001), and positively with serum creatinine (r = 0.72, p < 0.01) and urinary protein excretion (r = 0.85, p < 0.001). All RPGN patients developed end-stage renal disease, and 2 patients died shortly after treatment. Microscopic examination showed inflammatory cells within the glomeruli, and immunohistochemical study revealed abundant intrarenal T cells and macrophages in CrGN cases. Strong expression of OPN was observed in tubular epithelial cells and intraglomerular macrophages.
CONCLUSION: Cellular immune responses play a crucial role in glomerular crescents in renal amyloidosis. Immunosuppressive treatment is often ineffective and raises the risk of complications in CrGN with abundant glomerular sclerosis and tubulointerstitial injury.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19049702     DOI: 10.5414/cnp70464

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  3 in total

1.  Tocilizumab-induced remission of nephrotic syndrome accompanied by secondary amyloidosis and glomerulonephritis in a patient with rheumatoid arthritis.

Authors:  Shunsuke Yamada; Akihiro Tsuchimoto; Yoshiki Kaizu; Masatomo Taniguchi; Kosuke Masutani; Hiroshi Tsukamoto; Hiroaki Ooboshi; Kazuhiko Tsuruya; Takanari Kitazono
Journal:  CEN Case Rep       Date:  2014-07-29

2.  Sarcoidosis-associated renal AA amyloidosis and crescentic necrotizing glomerulonephritis.

Authors:  Albert Bui; Cherise Cortese; Nabeel Aslam
Journal:  Proc (Bayl Univ Med Cent)       Date:  2022-05-16

3.  Rapidly progressive glomerulonephritis due to coexistent anti-glomerular basement membrane disease and fibrillary glomerulonephritis.

Authors:  Wisit Cheungpasitporn; Claudia C Zacharek; Fernando C Fervenza; Lynn D Cornell; Sanjeev Sethi; Loren P Herrera Hernandez; Samih H Nasr; Mariam P Alexander
Journal:  Clin Kidney J       Date:  2015-11-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.